Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis

BACKGROUND: Daratumumab, a monoclonal antibody directed against CD38 is a recent class of drugs introduced into the multiple myeloma therapeutic landscape. While clinical trial data have shown a remarkable impact on outcomes, the efficacy of daratumumab combination therapies in specific clinically r...

Descripción completa

Detalles Bibliográficos
Autores principales: Mian, Hira, Eisfeld, Christine, Venner, Christopher P., Masih-Khan, Esther, Kardjadj, Moustafa, Jimenez-Zepeda, Victor H., Khandanpour, Cyrus, Lenz, Georg, McCurdy, Arleigh, Sebag, Michael, Song, Kevin, LeBlanc, Richard, White, Darrell, Stakiw, Julie, Reiman, Anthony, Louzada, Martha, Aslam, Muhammad, Kotb, Rami, Gul, Engin, Reece, Donna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894582/
https://www.ncbi.nlm.nih.gov/pubmed/35251992
http://dx.doi.org/10.3389/fonc.2022.826342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894582/
https://www.ncbi.nlm.nih.gov/pubmed/35251992
http://dx.doi.org/10.3389/fonc.2022.826342

Ejemplares similares